Helping People by Accelerating Research

The goal of the Krembil Foundation is to accelerate research, expand knowledge and ultimately impact lives through discoveries that will lead to scientific advancements in medicine.

INVESTING IN PEOPLE

The Krembil Foundation has invested over $120 million into research and community giving. Most of the funds have gone directly to medical research. The Foundation has supported over 100 researchers and partnered with over 75 organizations since its inception.

Learn More

Invested in over

175

UNIQUE PROJECTS

BUILDING PARTNERSHIPS

The Foundation strives to develop partnerships with its grantees. This means going above and beyond traditional grant oversight. The Foundation adopts a partnership role developing adaptive strategies in response to research or funding needs and forging connections between researchers all in the hopes of accelerating science.

Learn More

"We take a long-term approach to our research; continuously looking for scientists with whom we can build lasting partnerships."

Mark Krembil, President
ACTIVE GRANT

Dr. Carly Barr

Toronto Western Hospital

Collaborated with:

"Lorem ipsum dolor sit amet, consectetur adling elit. Duis non est sit amet felis port titor finibus."

John Smith

VIDEO
Active Grant - (2015-2018)

Functional Annotation of Genetic Variants Contributing to Immune Mediated Diseases

Funded Through:

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Curabitur blandit laoreet fring Vestibulum luctus dignissim eros vitae suscipit. Nullam feug iat luctus ligula nec dignis sim. Curabitur eget faucibus metus.

Immune-mediated diseases (IMDs) are characterized by misregulation of the immune system resulting in tissue and organ damage. IMDs such as rheumatoid arthritis, ankylosing spondylitis, and lupus are chronic and significantly impact the quality of life for affected individuals. Genome-wide association studies have identified common changes in regions of DNA in individuals with IMDs. Many of these changes have been found in regulatory regions of DNA called enhancers which regulate the expression of specific genes. Because enhancers often regulate the expression of genes that are very far from them, it has been challenging to predict the functional impact of DNA variants within these regions. Using high-throughput genetic technologies developed in her lab, Dr. Barr will determine the functional impact of DNA variants in enhancers by assessing how variants affect enhancer activity, and ultimately gene expression. This work will provide insight into which genes are affected, which is crucial to understanding the genetic basis of IMDs, identifying risk factors, and forming the basis for new treatments.

Publications
Past Grants

The Krembil Community